GSK plc - 02 Jul 2021 Form 4 Insider Report for CVRx, Inc. (CVRX)

Role
10%+ Owner
Signature
/s/ Victoria Whyte
Issuer symbol
CVRX
Transactions as of
02 Jul 2021
Net transactions value
+$4,950,000
Form type
4
Filing time
06 Jul 2021, 16:38:14 UTC
Previous filing
06 Jul 2021
Next filing
20 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVRX Common Stock Conversion of derivative security +1,505 +4.7% 33,316 02 Jul 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +12,979 +39% 46,295 02 Jul 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +14,917 +32% 61,212 02 Jul 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +8,380 +14% 69,592 02 Jul 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +27,345 +39% 96,937 02 Jul 2021 See Footnote F2, F4
transaction CVRX Common Stock Conversion of derivative security +635,646 +656% 732,583 02 Jul 2021 See Footnote F3, F4
transaction CVRX Common Stock Purchase $4,950,000 +275,000 +38% $18.00 1,007,583 02 Jul 2021 See Footnote F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVRX Series B-2 Preferred Stock Conversion of derivative security $0 -59,527 -100% $0.000000* 0 02 Jul 2021 Common Stock 1,505 See Footnote F2, F4
transaction CVRX Series C-2 Preferred Stock Conversion of derivative security $0 -513,312 -100% $0.000000* 0 02 Jul 2021 Common Stock 12,979 See Footnote F2, F4
transaction CVRX Series D-2 Preferred Stock Conversion of derivative security $0 -589,939 -100% $0.000000* 0 02 Jul 2021 Common Stock 14,917 See Footnote F2, F4
transaction CVRX Series E-2 Preferred Stock Conversion of derivative security $0 -331,399 -100% $0.000000* 0 02 Jul 2021 Common Stock 8,380 See Footnote F2, F4
transaction CVRX Series F-2 Preferred Stock Conversion of derivative security $0 -1,081,434 -100% $0.000000* 0 02 Jul 2021 Common Stock 27,345 See Footnote F2, F4
transaction CVRX Series G Preferred Stock Conversion of derivative security $0 -10,055,408 -100% $0.000000* 0 02 Jul 2021 Common Stock 635,646 See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering.
F2 The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F3 The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F4 The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
F5 The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.